Skip to main content

Table 1 Total NADC (lung, liver, and head and neck) patient characteristics, 2010-2014a

From: Changing Patterns of lung, liver, and head and neck non-AIDS-defining cancers relative to HIV status in Tanzania between 2002-2014

 

All NADCs

(N = 1127)

N (%)

Lung

(N = 101)

N (%)

Liver

(N = 151)

N (%)

Oral cavity/Oropharynxb

(N = 421)

N (%)

Nasal cavity/paranasal sinusesc

(N = 230)

N (%)

Hypopharynx/larynx/trachead

(N = 224)

N (%)

Female

410 (36.4%)

51 (50.5%)

63 (41.7%)

159 (37.8%)

98 (42.6%)

39 (17.4%)

Mean Age ± SD

54.3 ± 15.8

58.6 ± 13.8

47.1 ± 15.6

56.6 ± 15.2

47.9 ± 16.6

59.3 ± 13.4

Residence in Dar es Salaam

448 (39.8%)

53 (52.5%)

70 (46.4%)

140 (33.3%)

91 (39.6%)

95 (42.4%)

Smoking Status

 Previous

404 (35.9%)

33 (32.7%)

27 (17.9%)

170 (40.4%)

52 (22.6%)

122 (54.5%)

 Current

25 (2.2%)

2 (2.0%)

2 (1.3%)

12 (2.9%)

1 (0.4%)

8 (3.6%)

 Never

477 (42.3%)

39 (38.6%)

71 (47.0%)

169 (40.1%)

125 (54.4%)

73 (32.6%)

Alcohol use

 Previous

411 (36.5%)

30 (29.7%)

39 (25.8%)

182 (43.2%)

52 (22.6%)

108 (48.2%)

 Current

54 (4.8%)

5 (5.0%)

5 (3.3%)

19 (4.5%)

11 (4.8%)

14 (6.3%)

 Never

399 (35.4%)

31 (30.7%)

59 (39.1%)

143 (34.0%)

107 (46.5%)

59 (26.3%)

Tuberculosis

94 (8.3%)

26 (25.7%)

4 (8.0%)

32 (22.4%)

17 (22.4%)

15 (19.7%)

Co-morbiditiesf

 Mean count ± SD

0.46 ± 0.76

0.97 ± 0.98

0.77 + 0.93

0.37 ± 0.65

0.34 ± 0.67

0.34 ± 0.63

HIV-status

 Positive

81 (7.2%)

4 (4.0%)

11 (7.3%)

36 (8.6%)

22 (9.6%)

8 (3.6%)

 Negative

189 (16.8%)

26 (25.7%)

24 (16.0%)

87 (20.7%)

38 (16.5%)

14 (6.3%)

 Unknown

857 (76.0%)

71 (70.3%)

116 (76.8%)

298 (70.8%)

170 (73.9%)

202 (90.2%)

Advanced cancer stagee

655 (58.1%)

42 (41.6%)

49 (32.5%)

291 (98.0%)

135 (95.1%)

138 (85.7%)

Cancer Treatment Modality

 Radiotherapy

770 (68.3%)

32 (31.7%)

40 (29.0%)

332 (81.6%)

174 (80.9%)

192 (88.1%)

 Chemotherapy

574 (50.9%)

60 (59.4%)

87 (63.0%)

184 (45.3%)

128 (59.8%)

115 (52.5%)

 Both

414 (38.6%)

15 (14.9%)

25 (18.1%)

158 (38.7%)

112 (52.1%)

104 (47.3%)

Recurrence

41 (3.6%)

0

0

20 (4.8%)

18 (7.8%)

3 (1.3%)

Subsequent cancer diagnosis (at least one)

159 (14.1%)

34 (33.7%)

30 (19.9%)

37 (8.8%)

39 (17.0%)

19 (8.5%)

Recorded Death

149 (13.2%)

14 (13.9%)

33 (21.9%)

51 (12.1%)

27 (11.7%)

24 (10.7%)

  1. aTotals vary due to missing data
  2. bOral cavity/oropharynx cancers include oropharynx, parotid, tongue, oral cavity, soft/hard palate, lip, salivary gland, gingiva, intra-oral mandible, and tonsil according to WHO/IARC tumor classification
  3. cNasal cavity/paranasal sinuses cancers include maxilla, maxillary sinus, sinonasal, nasal, and nasopharynx according to WHO/IARC tumor classification
  4. dHypopharynx/larynx/trachea cancers include larynx, Hypopharynx, glottis, vallecula, pharynx, neck (non-skin), and submandibular according to WHO/IARC tumor classification
  5. eDefined as stages 3–4 and metastatic malignancies, % represents reported pathology department diagnosis
  6. fComorbidities include Comorbidities include malaria, pleural effusion, pneumonia, ascites, syphilis, liver cysts, oral thrush, oral ulcers, sinusitis, yellow fever, etc
Back to article page

Infectious Agents and Cancer

ISSN: 1750-9378

Contact us